A Phase 3 clinical trial investigating mavacamten for symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) completed its primary endpoint on March 6, 2025. This study, identified as NCT05582395, aims to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in this patient population.
Background
Hypertrophic cardiomyopathy (HCM) is a condition characterized by the thickening of the heart muscle, which can impede the heart's ability to pump blood effectively. Non-obstructive hypertrophic cardiomyopathy (nHCM) is a form of this condition where the thickening occurs without significant obstruction of blood flow from the left ventricle, leading to symptoms such as shortness of breath and chest pain.
Trial design
The study, NCT05582395, is a Phase 3, randomized, placebo-controlled trial. It enrolled 580 participants diagnosed with symptomatic non-obstructive hypertrophic cardiomyopathy. The primary objective of the study was to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in this specific patient population.
What this means
The primary completion of the Phase 3 trial for mavacamten in non-obstructive hypertrophic cardiomyopathy signifies that all participants have completed the study's primary observation period. This milestone indicates that the collected data will now undergo comprehensive analysis to determine the drug's efficacy and safety profile in this patient group. The results of this analysis will be crucial for understanding the potential role of mavacamten as a therapeutic option for individuals with nHCM.
Source
Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05582395, titled 'A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy,' was recorded on March 6, 2025, on clinicaltrials.gov.